The interaction between IL-6 and preL-HSPCs in our study (both in vitro Fig. 5 and in vivo Fig. 6) might have clinical relevance as anti-IL-6 treatments are available and can be used to control DNMT3A-driven CH. This evidence concerns the gene IL6 and cyclic hematopoiesis.